Abstract
Thyroid dysfunction is a well-recognised side-effect of treatment with interleukin-2 (IL2). We assessed the correlation between the development of abnormal thyroid function and tumour response in 13 patients receiving IL2 and interferon-2 alpha (IFN2 alpha) for advanced malignancy. Seven patients had normal thyroid function during treatment, and all of these patients have since died of progressive disease. Of six patients who did develop thyroid dysfunction during treatment, one patient has died of progressive disease. However, statistically we were unable to confirm a definite correlation between the development of thyroid dysfunction and survival in this small group of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reid, I., Sharpe, I., McDevitt, J. et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2α. Br J Cancer 64, 915–918 (1991). https://doi.org/10.1038/bjc.1991.426
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.426
This article is cited by
-
Hypothyroidism
Nature Reviews Disease Primers (2022)
-
Treatment-induced antibodies to interleukin-2
Biotherapy (1997)